Article Text

PDF
Injection therapies for plantar fasciopathy (‘plantar fasciitis’): a systematic review and network meta-analysis of 22 randomised controlled trials
  1. Konstantinos Tsikopoulos1,
  2. Haris S Vasiliadis2,
  3. Dimitris Mavridis3,4
  1. 11st Orthopaedic Department, 424 Army General Training Hospital, Thessaloniki, Greece
  2. 2Orthopaedie Sonnenhof, Bern, Switzerland
  3. 3Department of Hygiene and Epidemiology, University of Ioannina, Ioannina, Greece
  4. 4Department of Primary Education, University of Ioannina, Ioannina, Greece
  1. Correspondence to Konstantinos Tsikopoulos, 1st Orthopaedic Department, 424 Army General Training Hospital, Thessaloniki, Propylaion 8 Pefka Thessaloniki 57010, Greece; kostastsikop{at}gmail.com

Abstract

Objective To compare the efficacy of different injection therapies for plantar fasciopathy (historically known as ‘plantar fasciitis’).

Design Systematic review and network meta-analysis.

Data sources Electronic databases (MEDLINE, CENTRAL, Web of Science and Scopus) were searched up to 11 July 2015 for completed studies.

Eligibility criteria for selecting studies We considered randomised trials comparing various injection therapies in adults with plantar fasciopathy. The primary outcome was pain relief. Secondary outcomes included functional disability, composite and health-related outcomes. All outcomes were assessed (1) in the short term (up to 2 months), (2) the intermediate term (2–6 months) and (3) the medium term (more than 6 months to 2 years). Quality assessment was performed using the Cochrane risk of bias tool.

Results We included 22 trials comprising 1216 patients. Dehydrated amniotic membrane injections were significantly superior to corticosteroids in the short term in achieving the primary and composite outcomes (mean difference (MD) in visual analogue scale (VAS) was −7.32, 95% CIs −11.2 to −3.38; and MD in the foot health status questionnaire was 31.2, 95% CIs 13.9 to 48.6, respectively). For pain relief, botulinum toxin-A provided a significant short-term advantage over placebo, which was still present at 6 months (MD in VAS was −2.9, 95% CIs −4.44 to −1.39; and MD −4.34, 95% CIs −7.18 to −1.54, respectively).

Summary Although the dehydrated amniotic membrane provided significant clinical relief at 0–2 months, there were no data about this treatment at 2 months and beyond. Botulinum toxin-A injections significantly reduced pain intensity at 0–6 months.

Systematic review registration number CRD42015017353.

  • Meta-analysis
  • Intervention efficacy
  • Rehabilitation
  • Foot

Statistics from Altmetric.com

Footnotes

  • Contributors KT and HSV contributed to the study selection, data extraction and interpretation of the results. KT drafted the final version of the paper that was revised and approved by all authors. All authors of this systematic review and network meta-analysis contributed to the planning and reporting of the work.

  • Funding DM received research funding from the European Research Council (IMMA 260559).

  • Competing interests None declared.

  • Provenance and peer review Not commissioned; externally peer reviewed.

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.